Vyome Holdings (HIND) announced it has funded the budget for its VT-1953 Phase 3 study, which provides the company sufficient capital to fund the estimated costs to release Phase 3 interim results on the efficacy of its drug focused on symptoms of malignant fungating wounds. The company accomplished this funding need using its existing at-the-market facility.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIND:
- Vyome Holdings Highlights VT-1953 Market Potential Analysis
- Vyome’s LiveChain Signs LOI for Humanyze Note Acquisition
- Vyome Holdings: Promising Advancements in MFW Treatment and Strategic Market Positioning Drive Buy Rating
- Vyome Holdings announces VT-1953 trial achieves primary, secondary endpoints